{'52WeekChange': 1.087574,
 'SandP52WeekChange': None,
 'address1': 'Babraham Research Campus',
 'address2': 'Building 900',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 18.26,
 'askSize': 800,
 'averageDailyVolume10Day': 27712,
 'averageVolume': 47846,
 'averageVolume10days': 27712,
 'beta': None,
 'beta3Year': None,
 'bid': 16.01,
 'bidSize': 800,
 'bookValue': 5.325,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.26,
 'dayLow': 16.83,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.999,
 'enterpriseToRevenue': 23.582,
 'enterpriseValue': 201534816,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 16.882086,
 'fiftyTwoWeekHigh': 20.1,
 'fiftyTwoWeekLow': 6.24,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 2893121,
 'forwardEps': -2.06,
 'forwardPE': -8.305826,
 'fromCurrency': None,
 'fullTimeEmployees': 78,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.35101002,
 'heldPercentInstitutions': 0.33096,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/bicycletherapeutics.com',
 'longBusinessSummary': 'Bicycle Therapeutics plc, a clinical-stage '
                        'biopharmaceutical company, develops a class of '
                        'medicines for diseases that are underserved by '
                        'existing therapeutics. Its lead product candidate is '
                        'BT1718, a bicycle toxin conjugate (BTC), which is in '
                        'Phase I/IIa clinical trials targeting tumors that '
                        'express Membrane Type 1 matrix metalloprotease. The '
                        "company's oncology product candidates also comprise "
                        'BT5528, a BTC that is in a Phase I/IIa clinical trial '
                        'targeting EphA2; BT8009, which is in preclinical '
                        'studies targeting Nectin-4; and CD137, an immune cell '
                        'co-stimulatory molecule that is in preclinical stage. '
                        'In addition, it is developing THR-149, a plasma '
                        'kallikrein inhibitor that completed Phase I clinical '
                        'trials for the treatment of diabetic macular edema. '
                        'Further, the company collaborates with '
                        'biopharmaceutical companies and organizations to '
                        'develop programs in therapeutic areas, such as '
                        'anti-infective, cardiovascular, ophthalmology, and '
                        'respiratory indications. Bicycle Therapeutics plc has '
                        'a clinical trial and license agreement with the '
                        'Cancer Research Technology Limited and CRUK; research '
                        'collaboration agreements with AstraZeneca, Sanofi, '
                        'Oxurion, and the Dementia Discovery Fund; and '
                        'discovery collaboration and license agreement with '
                        'Genentech for the discovery and development of '
                        'Bicycle peptides for multiple immuno-oncology '
                        'targets. The company was incorporated in 2009 and is '
                        'headquartered in Cambridge, the United Kingdom.',
 'longName': 'Bicycle Therapeutics plc',
 'market': 'us_market',
 'marketCap': 309480544,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_72510621',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -35429000,
 'nextFiscalYearEnd': 1640908800,
 'open': 18.22,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 1223 261 503',
 'previousClose': 17.64,
 'priceHint': 2,
 'priceToBook': 3.2131457,
 'priceToSalesTrailing12Months': 36.213497,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.26,
 'regularMarketDayLow': 16.83,
 'regularMarketOpen': 18.22,
 'regularMarketPreviousClose': 17.64,
 'regularMarketPrice': 18.22,
 'regularMarketVolume': 15817,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 18087700,
 'sharesPercentSharesOut': 0.0056,
 'sharesShort': 100906,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 104596,
 'shortName': 'Bicycle Therapeutics plc',
 'shortPercentOfFloat': None,
 'shortRatio': 3.28,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'BCYC',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.988,
 'twoHundredDayAverage': 14.548259,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ce2103f4-bc89-3b95-8a05-b5941ff8789d',
 'volume': 15817,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.bicycletherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'CB22 3AT'}